Abstract
OBJECTIVE:
To examine the long-term effects of treatment with recombinant human CuZn superoxide dismutase (rhSOD) in infants enrolled previously in two placebo-controlled trials.
STUDY DESIGN:
Records for 46 (88%) infants were examined, with 19 infants having received either single or multiple intratracheal (i.t.) doses of placebo, 12 having received a single i.t. dose of rhSOD, and 15 having received multiple i.t. doses of rhSOD. Mean age at follow-up was 28 months corrected age. Records were examined for neurologic dysfunction, developmental delay, and any significant medical disorders.
RESULTS:
Four placebo infants (21%) had evidence of neurodevelopmental abnormalities and four infants developed asthma. Four single-dose rhSOD infants (33%) had neurodevelopmental abnormalities and two infants developed asthma. One multiple-dose rhSOD infant had evidence ofneurodevelopmental abnormalities and one developed asthma. No other differences were found between the placebo and rhSOD groups.
CONCLUSION: Preliminary data suggest that rhSOD is safe and not associated with any long-term adverse effects. Further results will depend on the results of multicenter trials of rhSOD in preterm infants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, J., Richter, S., Biswas, S. et al. Long-Term Follow-up of Premature Infants Treated With Prophylactic, Intratracheal Recombinant Human CuZn Superoxide Dismutase. J Perinatol 20, 213–216 (2000). https://doi.org/10.1038/sj.jp.7200363
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7200363